Ketamine

Beckley Waves Celebrates a Year of Milestones, Including $3.3 Million in New Funding, 200 Retreat Participants, the Inaugural Cohort of Therapist Training, and the Acquisition of Ketamine Therapy Provider Nue Life

Retrieved on: 
Tuesday, March 5, 2024

Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.

Key Points: 
  • Through its portfolio of operating companies, Beckley Waves has also expanded programs for practitioner training and psilocybin retreats, accelerating the company’s growth.
  • In September, the company also acquired at-home ketamine therapy provider Nue Life and will continue Nue Life’s work to provide safe and scalable access to ketamine-assisted therapy in underserved areas across multiple US states.
  • In 2024, Beckley Retreats will offer dedicated retreats in Jamaica and the Netherlands that will be exclusively for women, veterans, and the BIPOC community.
  • "With our ongoing momentum, we will keep the flywheel spinning and continue to allow the Beckley Waves Ecosystem to play a catalytic role in our shared path to widespread access."

SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds

Retrieved on: 
Tuesday, February 27, 2024

The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.

Key Points: 
  • The patent applications refer to novel proprietary compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”), the active ingredient of SciSparc's proprietary CannAmide™.
  • These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (“USPTO”).
  • As part of this collaboration, eight other applications have been filed by Clearmind with the USPTO for various combinations, three of which are for the combination of PEA with Clearmind’s 5-methoxy-2-aminoindane compound for the treatments of alcohol use disorder, cocaine addiction and obesity and its related metabolic disorders.
  • In addition, seven applications were filed under the PCT.

Beckley Academy Publishes First Open-Source Learning Framework to Advance Psychedelic-Assisted Therapy Training Standards

Retrieved on: 
Tuesday, February 27, 2024

NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .

Key Points: 
  • NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Beckley Academy , the learning studio that prepares and trains practitioners to provide psychedelic-assisted therapy (PAT) with Ketamine, Psilocybin, and MDMA, announced today the open-source publication of its research: A Psychedelic-Assisted Therapy Learning Framework .
  • This industry-first learning framework will serve as a much-needed foundation to advance national training standards for clinicians to provide ethical and effective psychedelic-assisted therapy.
  • Currently, no national training standards or certifications exist for psychedelic practitioners, though many organizations have independently created training programs, practice guidelines, and codes of ethics.
  • Beckley Academy co-founding team members Deborah Gardner and Shirelle Noble recognized the opportunity to analyze existing publications and create a unified framework.

Six Years Strong: Founder of Revitalist Kathryn Walker’s Continuous Leadership in Revolutionizing Mental Health Care

Retrieved on: 
Friday, February 23, 2024

The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.

Key Points: 
  • The COVID-19 pandemic especially, has exacerbated mental health issues, with increased mood disorders, substance use, and suicidal ideation rates.
  • Kate NeuroPsych represents a groundbreaking approach to mental health care — offering 24/7 availability, personalized recommendations, and worldwide access — being designed by scientific leaders who are positively disrupting healthcare delivery at Revitalist and Sama Therapeutics .
  • Looking ahead, Kathryn envisions a future where psychedelics are normalized as essential tools in mental health care.
  • With each milestone she achieves, Kathryn Walker continues to redefine the boundaries of mental health care and inspire hope for a brighter, more compassionate future.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

NRx Pharmaceuticals (Nasdaq:NRXP) Launches HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

Retrieved on: 
Monday, February 26, 2024

RADNOR, Pa., Feb. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals," the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman and Chief Scientist of NRx Pharmaceuticals, will present a corporate overview at the BIO CEO & Investor Conference, which is scheduled to take place February 26-27, 2024, at the Marriott Marquis in New York City. Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics. The presentation will be available on the NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/.

Key Points: 
  • Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics.
  • The presentation will be available on the NRx Pharmaceuticals website at https://www.nrxpharma.com/hope-therapeutics/ .
  • Additionally, we will be updating investors with regard to our plans to add a digital therapeutic component to our ketamine offering that has potential to extend the clinical benefit to patients."
  • "We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy."

The Inner Circle Acknowledges, Lisa M. Basilli Pinnacle Lifetime Member

Retrieved on: 
Thursday, February 22, 2024

DALLAS, Feb. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lisa M. Basilli is acknowledged as a Pinnacle Lifetime Member for her contributions to the field of Anesthesiology and Ketamine Infusion Therapy.

Key Points: 
  • DALLAS, Feb. 22, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Lisa M. Basilli is acknowledged as a Pinnacle Lifetime Member for her contributions to the field of Anesthesiology and Ketamine Infusion Therapy.
  • Dr. Basilli pursued higher education at Texas A & M University where she earned a Bachelor of Science degree in Microbiology.
  • An expert in anesthesiology and ketamine infusion therapy for mental health disorders, Dr. Basilli is a member of the American Medical Association (AMA) and the Texas Medical Association.
  • Looking to the future, she plans to continue her work in ketamine infusion therapy and her involvement with Sound Physicians.

Avesta Partners with Veterans Affairs (VA) to Offer Free Ketamine Therapy to Eligible Veterans

Retrieved on: 
Wednesday, February 21, 2024

WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- Avesta Ketamine and Wellness ("Avesta"), a leading provider of innovative mental health treatments, announced a partnership with Veterans Affairs (VA) to offer free ketamine therapy to eligible veterans. This initiative, available now in Avesta ketamine clinics across Washington, DC, Northern Virginia, and Bethesda, Maryland, will help veterans overcome treatment-resistant depression (TRD), PTSD, anxiety, chronic pain, and substance misuse disorders.

Key Points: 
  • WASHINGTON, Feb. 21, 2024 /PRNewswire/ -- Avesta Ketamine and Wellness ("Avesta"), a leading provider of innovative mental health treatments, announced a partnership with Veterans Affairs (VA) to offer free ketamine therapy to eligible veterans.
  • Avesta seeks to address these challenges by offering IV ketamine infusions and/or Spravato treatments to veterans who have not found relief through traditional therapies.
  • Avesta already partners with the Veterans Mental Health Coalition, a coalition committed to ending veterans' suicide, and views this new partnership as continuing its mission.
  • Thanks to Avesta's Veterans Care Agreement, veterans near McLean, Virginia, Bethesda, Maryland, and Washington D.C. are eligible to receive treatments at Avesta without financial burden.

NRx Pharmaceuticals (Nasdaq:NRXP) to Launch HOPE Therapeutics, Inc. at the BIO CEO & Investor Conference 2024

Retrieved on: 
Tuesday, February 20, 2024

Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics.

Key Points: 
  • Presenting with him will be Matthew Duffy, the newly-appointed co-CEO of HOPE Therapeutics.
  • Concurrent with the presentation, NRx plans to file a proxy statement, subject to board approval, for Nasdaq:NRXP shareholders outlining the share structure and seeking a shareholder advisory vote to support the planned share dividend for HOPE Therapeutics.
  • The Company has received consistent advice from public shareholders that the planned share dividend and royalty coupon be distributed only to shareholders and warrant-holders who execute a covenant not to participate in short sales of the Company's stock.
  • "We thank our investors for their support and look forward to updating the public on our progress towards building a lifesaving therapy."